An Online Survey of Caregivers of Patients with SCN8A-Related Epilepsy

Celene Grayson¹, Alison Cutts¹, Constanza Luzon¹, Noam Butterfield¹, Hillary Savoie², Michael Hammer³, John Schreiber⁴, Dietrich Haubenberger⁵, Simon N. Pimstone¹, Ernesto Aycardi¹, Cynthia Harden¹

¹ Xenon Pharmaceuticals Inc.; ² The Cute Syndrome Foundation; ³ Shay Emma Hammer Foundation and University of Arizona; ⁴ Children’s National Medical Center; ⁵ Neurocrine Biosciences Inc.
Disclosures

• Drs. Harden, Cutts, Grayson, Luzon, Butterfield, Pimstone and Aycardi are employed by Xenon Pharmaceuticals Inc. (“Xenon”). They receive salaries and may hold stock or stock options in Xenon.

• The Cute Syndrome Foundation received funds from Xenon for this patient survey and other projects/events. In addition, Dr. Savoie is a consultant for Xenon as an employee of Cute Syndrome Consultants, LLC. Cute Syndrome Consultants, LLC receives financial compensation from Xenon in exchange for Dr. Savoie’s services.

• The Shay Emma Hammer Foundation and the University of Arizona received funds from Xenon for an SCN8A patient registry but not directly for this patient survey. In addition, Dr. Hammer is, in a personal capacity, a consultant for Xenon and receives financial compensation from Xenon in exchange for his services.

• Dr. Schreiber, in a personal capacity, is a consultant for Xenon and receives financial compensation from Xenon in exchange for his services.

• Dr. Hammer and Dr. Schreiber, in their personal capacities, are consultants for Neurocrine Biosciences, Inc. and receive financial compensation from Neurocrine Biosciences in exchange for their services.

• Dr. Haubenberger is employed by Neurocrine Biosciences, Inc. He receives a salary and may hold stock or stock options in Neurocrine Biosciences.

• Neurocrine Biosciences, Inc. has an exclusive license to XEN901 and other pre-clinical selective Na_v1.6 inhibitors and dual Na_v1.2/1.6 inhibitors.

• All trademarks are the property of their respective owners.
Background

- XEN901 was developed as a precision medicine to selectively address the etiology of SCN8A-DEE
- Selective inhibition of Na\textsubscript{v}1.6 channel
- Does not inhibit other sodium channels
- On Dec. 2, 2019, Neurocrine Biosciences obtained an exclusive license to XEN901 (now known as NBI-921352)
Survey Objectives and Methods

• A caregiver survey was performed to obtain additional phenotypic information regarding the history of SCN8A-related epilepsy as well as Anti-Seizure Medication (ASM)

• Demographics, comorbidities, seizure onset and frequency, ASM use

• 36 question survey, conducted by Xenon in collaboration with The Cute Syndrome Foundation

• Implemented by M3 Global research and reviewed and approved by Veritas Independent Review Board

• Families recruited by targeted email outreach, social media campaign and an educational webinar

• Survey responses collected over a three-week period in late 2019
# Results

## Preliminary Demographics and Seizure Burden of Survey Patients

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data available</strong></td>
<td>125 complete responses for analysis; exclusions as follows: 2 non-English speaking origin</td>
</tr>
<tr>
<td><strong>Locations (n=123)</strong></td>
<td>USA (93); Canada (12); UK (12) Australia (6)</td>
</tr>
</tbody>
</table>
| **Patient Age, n (%)**                            | 30 (24%) younger than 4 years  
93 (76%) older than 4 years                                                                                                               |
| **Seizure history, n (%)**                         | 8 (7%) report no seizure history  
115 (93%) report seizure history                                                                                                           |
| **Spectrum of Seizure Onset (for those with onset in the first 2 years; n=107)**          | Average age of seizure onset was ~4 months  
Range was 1 day to 24 months                                                                                                                 |
| **Initial seizure frequency (n=115)**              | 15% had more than 10 seizures per day  
30% had between 2-10 seizures per day  
12% had 1 seizure per day                                                                                                                    |
| **Current seizure frequency (n=109)**              | 63% had seizures over past 30 days  
71% had seizures over past 90 days  
79% had seizures over past 180 days                                                                                                           |
Results

Spectrum of Clinical Presentation

- Seizures: 90%
- No seizures: 0%
- Movement disorder: 40%
- Hypotonia: 50%
- Autism: 20%
- Intellectual Disability: 70%
- Swallowing problems/GT Feeding: 40%
- Visual Impairment: 10%
Results
Current ASM Use (reported by ≥4 respondents)
"Best" and "Worst" Medications for Seizure Control*

* Reported as "worst" due to undesirable side effects or lack of efficacy
Response to Anti-Seizure Medications (Data From Other Studies)

Levetiracetam (Keppra)

- Failed: 64%
- Success: 11%
- Neither: 6%
- Not Tried: 8%

SCN8A Registry

SCN8A Multidisciplinary Clinic
Genetic Diagnosis

Approximate time to diagnosis after first seizure is decreasing

![Bar chart showing average time to diagnosis in months for different age groups of patients.](chart.png)

- **4 to <6 years**: Average time to diagnosis is around 12 months.
- **2 to <4 years**: Average time to diagnosis is around 6 months.
- **1 to <2 years**: Average time to diagnosis is around 4 months.
- **<1 year**: Average time to diagnosis is around 2 months.
Conclusions

• Survey helps to improve the knowledge of disease course and phenotypic heterogeneity
• Time to genetic diagnosis from first seizure is decreasing over time
• Broad use of ASMs is apparent in this population and survey confirmed observations from previous studies that Levetiracetam (Keppra), although commonly used as a first line treatment, may not be recommended for use in SCN8A-related epilepsy
• Study limitations include retrospective report with possible memory bias

Phase 2 Clinical Planning:

• Survey was informative regarding clinical trial design
• Completed development of a pediatric-specific granule formulation of XEN901/NBI-921352
• Completed juvenile toxicology studies to support pediatric development activities
• PK study in healthy adult volunteers with the new pediatric formulation ongoing
• Neurocrine Biosciences anticipates filing an IND application with the FDA in mid-2020 in order to start a Phase 2 clinical trial in SCN8A-DEE patients in the second half of 2020